VIVUS Inc. (VVUS)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.06+0.02 (+1.92%)
At close: 4:00 PM EDT
People also watch:
OREXARNAKERXAMRNXOMA
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open1.03
Prev Close1.04
Bid1.02 x 3000
Ask1.11 x 2400
Day's Range1.03 - 1.07
52wk Range0.92 - 2.25
1y Target EstN/A
Market Cap110.43M
P/E Ratio (ttm)-2.10
Beta0.34
Volume192,719
Avg Vol (3m)604,167
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Capital Cubeyesterday

    ETF’s with exposure to VIVUS, Inc. : August 26, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to VIVUS, Inc. Here are 5 ETF’s with the largest exposure to VVUS-US. Comparing the performance and risk of VIVUS, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • Capital Cube15 days ago

    ETF’s with exposure to VIVUS, Inc. : August 12, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETF’s with exposure to VIVUS, Inc. Here are 5 ETF’s with the largest exposure to VVUS-US. Comparing the performance and risk of VIVUS, Inc. with the ETF’s that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)

  • VIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016
    Capital Cube16 days ago

    VIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2016 By the Numbers : August 11, 2016

    Categories: Yahoo Finance Click here to see latest analysis VIVUS, Inc. reports financial results for the quarter ended June 30, 2016. We analyze the earnings along side the following peers of VIVUS, Inc. – Apricus Biosciences, Inc., Pfizer Inc., AmerisourceBergen Corporation, Eli Lilly and Company, Cardinal Health, Inc., Repros Therapeutics Inc., Sophiris Bio Inc. and Arena Pharmaceuticals, Inc. ... Read more (Read more...)